Biomarin Pharmaceutical (BMRN) Amortization of Deferred Charges (2016 - 2025)
Historic Amortization of Deferred Charges for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Q3 2025 value amounting to $649000.0.
- Biomarin Pharmaceutical's Amortization of Deferred Charges fell 961.0% to $649000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 2873.41%. This contributed to the annual value of $3.4 million for FY2024, which is 1979.47% down from last year.
- According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Amortization of Deferred Charges is $649000.0, which was down 961.0% from $660000.0 recorded in Q2 2025.
- Over the past 5 years, Biomarin Pharmaceutical's Amortization of Deferred Charges peaked at $1.1 million during Q3 2023, and registered a low of $649000.0 during Q3 2025.
- Over the past 5 years, Biomarin Pharmaceutical's median Amortization of Deferred Charges value was $1.0 million (recorded in 2022), while the average stood at $935736.8.
- Per our database at Business Quant, Biomarin Pharmaceutical's Amortization of Deferred Charges crashed by 8027.52% in 2021 and then surged by 1100.29% in 2023.
- Biomarin Pharmaceutical's Amortization of Deferred Charges (Quarter) stood at $1.0 million in 2021, then decreased by 0.39% to $1.0 million in 2022, then dropped by 3.7% to $990000.0 in 2023, then plummeted by 33.33% to $660000.0 in 2024, then decreased by 1.67% to $649000.0 in 2025.
- Its last three reported values are $649000.0 in Q3 2025, $660000.0 for Q2 2025, and $660000.0 during Q1 2025.